HRP20171795T1 - Dvojni selektivni inhibitori pi3 delta i gamma kinaze - Google Patents
Dvojni selektivni inhibitori pi3 delta i gamma kinaze Download PDFInfo
- Publication number
- HRP20171795T1 HRP20171795T1 HRP20171795TT HRP20171795T HRP20171795T1 HR P20171795 T1 HRP20171795 T1 HR P20171795T1 HR P20171795T T HRP20171795T T HR P20171795TT HR P20171795 T HRP20171795 T HR P20171795T HR P20171795 T1 HRP20171795 T1 HR P20171795T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- disease
- compound according
- intended
- lymphoma
- Prior art date
Links
- 230000009977 dual effect Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 5
- 108091000080 Phosphotransferase Proteins 0.000 claims 5
- 102000020233 phosphotransferase Human genes 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 230000003197 catalytic effect Effects 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 102000038030 PI3Ks Human genes 0.000 claims 3
- 108091007960 PI3Ks Proteins 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- HDXDQPRPFRKGKZ-INIZCTEOSA-N 3-(3-fluorophenyl)-2-[(1s)-1-(7h-purin-6-ylamino)propyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3NC=NC=3N=CN=2)CC)OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HDXDQPRPFRKGKZ-INIZCTEOSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- HDXDQPRPFRKGKZ-MRXNPFEDSA-N 3-(3-fluorophenyl)-2-[(1R)-1-(7H-purin-6-ylamino)propyl]chromen-4-one Chemical compound CC[C@@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1 HDXDQPRPFRKGKZ-MRXNPFEDSA-N 0.000 claims 1
- HDXDQPRPFRKGKZ-UHFFFAOYSA-N 3-(3-fluorophenyl)-2-[1-(7h-purin-6-ylamino)propyl]chromen-4-one Chemical compound N=1C=NC=2N=CNC=2C=1NC(CC)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HDXDQPRPFRKGKZ-UHFFFAOYSA-N 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (19)
1. Spoj, naznačen time što se bira između 2-(1-(9H-purin-6-ilamino)propil)-3-(3-fluorfenil)-4H-kromen-4-ona i njegovih farmaceutski prihvatljivih soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se spoj bira između (S)-2-(1-(9H-purin-6-ilamino)propil)-3-(3-fluorfenil)-4H-kromen-4-ona i njegovih farmaceutski prihvatljivih soli.
3. Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je spoj (S)-2-(1-(9H-purin-6-ilamino)propil)-3-(3-fluorfenil)-4H-kromen-4-on.
4. Spoj u skladu s patentnim zahtjevom 2 ili patentnim zahtjevom 3, naznačen time što spoj uglavnom ne sadrži (R)-2-(1-(9H-purin-6-ilamino)propil)-3-(3-fluorfenil)-4H-kromen-4-on i njegove farmaceutski prihvatljive soli.
5. Spoj u skladu s patentnim zahtjevom 2 ili patentnim zahtjevom 3, naznačen time što spoj ima enantiomerni suvišak veći od otprilike 95%.
6. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-5 i najmanje jednu farmaceutski prihvatljivu podlogu.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi u inhibiranju katalitičke aktivnosti PI3 δ kinaze prisutne u stanici stavljanjem u kontakt stanice s djelotvornom količinom navedenog spoja.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi u inhibiranju katalitičke aktivnosti PI3 γ kinaze prisutne u stanici, stavljanjem u kontakt stanice s djelotvornom količinom navedenog spoja.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi u inhibiranju katalitičke aktivnosti PI3 δ kinaze i PI3 γ kinaze prisutne u stanici, stavljanjem u kontakt stanice s djelotvornom količinom navedenog spoja.
10. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 7-9, naznačen time što se inhibiranje provodi kod subjekta koji boluje od bolesti, poremećaja ili stanja koje se bira između raka, poremećaja kostiju, upalne bolesti, imunosne bolesti, bolesti živčanog sustava, metaboličke bolesti, dišne bolesti, tromboze i srčane bolesti.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi u liječenju leukemije kod pacijenta kojem je to potrebno, koje se sastoji u primjeni djelotvorne količine navedenog spoja.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi u liječenju astme ili kronične opstruktivne plućne bolesti kod pacijenta kojem je to potrebno, koje se sastoji u primjeni djelotvorne količine navedenog spoja.
13. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi u liječenju reumatoidnog artritisa, psorijaze, lupusa ili eksperimentalnog autoimunog encefalomijelitisa (EAE) kod pacijenta kojem je to potrebno, koje se sastoji u primjeni djelotvorne količine navedenog spoja.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi u liječenju kronične limfocitne leukemije (CLL), nehodgkinovskog limfoma (NHL), Hodgkinovog limfoma (HL), akutne mijeloidne leukemije (AML), multiplog mijeloma (MM), limfoma malih limfocita (SLL) ili bezbolnog nehodgkinovskog limfoma (I-NHL) kao bolesti kod pacijenta kojem je to potrebno, koje se sastoji u primjeni djelotvorne količine navedenog spoja.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi u liječenju bolesti, poremećaja ili stanja kojem bi pogodovalo inhibiranje katalitičke aktivnosti PI3 δ/γ kinaze.
16. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je namijenjen upotrebi u liječenju bolesti, poremećaja ili stanja povezanog s PI3K koje se sastoji u primjeni na subjektu kojem je to potrebno djelotvorne količine navedenog spoja.
17. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 16, naznačen time što se upotreba dodatno sastoji u primjeni dodatnog aktivnog sredstva, koje se bira između sredstava protiv raka, protuupalnih sredstava, imunosupresivnih sredstava, steroida, nesteroidnih protuupalnih sredstava, antihistaminika, analgetika i njihovih smjesa.
18. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 16, naznačen time što je bolest, poremećaj ili stanje povezano s PI3K bolest povezana s imunosnim sustavom, bolest ili poremećaj koji uključuje upalu, rak ili koju drugu proliferativnu bolest, bolest ili poremećaj jetre, ili bolest ili poremećaj bubrega.
19. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 16, naznačen time što se bolest, poremećaj ili stanje povezano s PI3K bira između leukemije, akutne limfocitne leukemije, akutne limfoblastične leukemije, limfoma B-stanica, limfoma T-stanica, Hodgkinovog limfoma, nehodgkinovskog limfoma, limfoma vlasastih stanica, Burkettovog limfoma, akutne i kronične mijelogene leukemije, mijelodisplastičnog sindroma i promijelocitne leukemije, psorijaze, reumatoidnog artritisa, osteoartritisa, astme, COPD, alergijskog rinitisa i eritematoznog lupusa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2501CH2013 | 2013-06-07 | ||
| IN5567CH2013 | 2013-12-03 | ||
| PCT/IB2014/061954 WO2014195888A1 (en) | 2013-06-07 | 2014-06-04 | Dual selective pi3 delta and gamma kinase inhibitors |
| EP14732019.6A EP3004106B1 (en) | 2013-06-07 | 2014-06-04 | Dual selective pi3 delta and gamma kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171795T1 true HRP20171795T1 (hr) | 2018-01-26 |
Family
ID=50980341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171795TT HRP20171795T1 (hr) | 2013-06-07 | 2017-11-20 | Dvojni selektivni inhibitori pi3 delta i gamma kinaze |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US9790224B2 (hr) |
| EP (1) | EP3004106B1 (hr) |
| JP (1) | JP6499165B2 (hr) |
| KR (1) | KR102292853B1 (hr) |
| CN (1) | CN105358560B (hr) |
| AP (1) | AP2015008888A0 (hr) |
| AR (1) | AR096543A1 (hr) |
| AU (1) | AU2014276476B2 (hr) |
| BR (1) | BR112015030385B1 (hr) |
| CA (1) | CA2913226C (hr) |
| CL (1) | CL2015003562A1 (hr) |
| CY (1) | CY1119615T1 (hr) |
| DK (1) | DK3004106T3 (hr) |
| EA (1) | EA029017B1 (hr) |
| ES (1) | ES2648094T3 (hr) |
| HK (1) | HK1217949A1 (hr) |
| HR (1) | HRP20171795T1 (hr) |
| HU (1) | HUE035237T2 (hr) |
| IL (1) | IL242761B (hr) |
| LT (1) | LT3004106T (hr) |
| MX (1) | MX366449B (hr) |
| NO (1) | NO3004106T3 (hr) |
| PH (1) | PH12015502698A1 (hr) |
| PL (1) | PL3004106T3 (hr) |
| PT (1) | PT3004106T (hr) |
| RS (1) | RS56606B1 (hr) |
| SG (1) | SG11201509992RA (hr) |
| SI (1) | SI3004106T1 (hr) |
| TW (1) | TWI615144B (hr) |
| WO (1) | WO2014195888A1 (hr) |
| ZA (1) | ZA201508708B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3154024C (en) | 2010-06-03 | 2024-02-27 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma |
| MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
| JP6501270B2 (ja) | 2013-03-14 | 2019-04-17 | ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ | 標的化剤抗体抱合体およびその使用 |
| SG11201509992RA (en) * | 2013-06-07 | 2016-01-28 | Rhizen Pharmaceuticals Sa | Dual selective pi3 delta and gamma kinase inhibitors |
| SG11201510011VA (en) | 2013-06-07 | 2016-01-28 | California Inst Biomedical Res | Small molecule inhibitors of fibrosis |
| EP3250036B1 (en) | 2014-12-10 | 2021-05-12 | The Scripps Research Institute | Small molecule inhibitors of fibrosis |
| MX2017008486A (es) * | 2014-12-23 | 2017-09-19 | Pharmacyclics Llc | Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion. |
| US20200289520A1 (en) * | 2017-12-06 | 2020-09-17 | Rhizen Pharmaceuticals Sa | Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma |
| WO2021229452A1 (en) | 2020-05-14 | 2021-11-18 | Rhizen Pharmaceuticals Ag | Purine derivatives as sik-3 inhibitors |
| WO2023125418A1 (zh) * | 2021-12-31 | 2023-07-06 | 同润生物医药(上海)有限公司 | 一种苯磺酸盐结晶及其制备方法 |
| WO2023125419A1 (zh) * | 2021-12-31 | 2023-07-06 | 同润生物医药(上海)有限公司 | 一种己二酸盐结晶及其制备方法 |
| TW202328132A (zh) * | 2021-12-31 | 2023-07-16 | 大陸商同潤生物醫藥(上海)有限公司 | ＰＩ３Ｋδ／γ雙重抑制劑化合物的半富馬酸鹽結晶及其製備方法 |
| WO2023130334A1 (zh) * | 2022-01-07 | 2023-07-13 | 同润生物医药(上海)有限公司 | 一种色烯-4-酮化合物及其中间体的制备方法 |
| WO2023209634A1 (en) | 2022-04-29 | 2023-11-02 | Rhizen Pharmaceuticals Ag | A dual selective pi3k delta and gamma inhibitors and/or a salt-inducible kinase 3 inhibitor for treating solid tumors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5889795B2 (ja) * | 2009-11-05 | 2016-03-22 | ライゼン・ファーマシューティカルズ・エスアー | 新規キナーゼモジュレーター |
| AR084366A1 (es) | 2010-12-20 | 2013-05-08 | Incyte Corp | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k |
| PT2705029T (pt) * | 2011-05-04 | 2019-02-01 | Rhizen Pharmaceuticals S A | Novos compostos como moduladores de proteína quinases |
| BR112014027470A2 (pt) | 2012-05-04 | 2017-06-27 | Rhizen Pharmaceuticals S A | novo processo para preparação de derivados 2-(1-hidroxi-alquilo)-cromen-4-ona oticamente puros e opcionalmente substituídos e seu uso na preparação de produtos farmacêuticos. |
| SG11201509992RA (en) * | 2013-06-07 | 2016-01-28 | Rhizen Pharmaceuticals Sa | Dual selective pi3 delta and gamma kinase inhibitors |
| US20200289520A1 (en) * | 2017-12-06 | 2020-09-17 | Rhizen Pharmaceuticals Sa | Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma |
-
2014
- 2014-06-04 SG SG11201509992RA patent/SG11201509992RA/en unknown
- 2014-06-04 WO PCT/IB2014/061954 patent/WO2014195888A1/en active Application Filing
- 2014-06-04 HU HUE14732019A patent/HUE035237T2/hu unknown
- 2014-06-04 ES ES14732019.6T patent/ES2648094T3/es active Active
- 2014-06-04 RS RS20171183A patent/RS56606B1/sr unknown
- 2014-06-04 AU AU2014276476A patent/AU2014276476B2/en active Active
- 2014-06-04 EA EA201592113A patent/EA029017B1/ru unknown
- 2014-06-04 NO NO14732019A patent/NO3004106T3/no unknown
- 2014-06-04 JP JP2016517722A patent/JP6499165B2/ja active Active
- 2014-06-04 PT PT147320196T patent/PT3004106T/pt unknown
- 2014-06-04 CA CA2913226A patent/CA2913226C/en active Active
- 2014-06-04 KR KR1020167000160A patent/KR102292853B1/ko active IP Right Grant
- 2014-06-04 EP EP14732019.6A patent/EP3004106B1/en active Active
- 2014-06-04 SI SI201430486T patent/SI3004106T1/en unknown
- 2014-06-04 BR BR112015030385-4A patent/BR112015030385B1/pt active IP Right Grant
- 2014-06-04 PL PL14732019T patent/PL3004106T3/pl unknown
- 2014-06-04 CN CN201480032576.4A patent/CN105358560B/zh active Active
- 2014-06-04 AP AP2015008888A patent/AP2015008888A0/xx unknown
- 2014-06-04 LT LTEP14732019.6T patent/LT3004106T/lt unknown
- 2014-06-04 DK DK14732019.6T patent/DK3004106T3/en active
- 2014-06-04 US US14/295,875 patent/US9790224B2/en active Active
- 2014-06-04 MX MX2015016741A patent/MX366449B/es active IP Right Grant
- 2014-06-06 AR ARP140102206A patent/AR096543A1/es not_active Application Discontinuation
- 2014-06-06 TW TW103119720A patent/TWI615144B/zh active
-
2015
- 2015-11-24 IL IL242761A patent/IL242761B/en active IP Right Grant
- 2015-11-26 ZA ZA2015/08708A patent/ZA201508708B/en unknown
- 2015-12-03 PH PH12015502698A patent/PH12015502698A1/en unknown
- 2015-12-04 CL CL2015003562A patent/CL2015003562A1/es unknown
-
2016
- 2016-05-25 HK HK16105982.1A patent/HK1217949A1/zh unknown
-
2017
- 2017-08-08 US US15/672,061 patent/US10851107B2/en active Active
- 2017-11-20 HR HRP20171795TT patent/HRP20171795T1/hr unknown
- 2017-11-21 CY CY20171101216T patent/CY1119615T1/el unknown
-
2020
- 2020-05-01 US US16/865,034 patent/US11466006B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171795T1 (hr) | Dvojni selektivni inhibitori pi3 delta i gamma kinaze | |
| RU2017143776A (ru) | Пролекарства альвоцидиба, имеющие повышенную биодоступность | |
| HRP20160361T1 (hr) | Terapija u kombinaciji s antitumorskim alkaloidom | |
| JP2015516434A5 (hr) | ||
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| JP2014521735A5 (hr) | ||
| NZ703851A (en) | Compounds that are s1p modulating agents and/or atx modulating agents | |
| JP2014511892A5 (hr) | ||
| WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
| JP2012193216A5 (hr) | ||
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| JP2013519675A5 (hr) | ||
| JP2014502641A5 (hr) | ||
| EA033113B1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| JP2015532296A5 (hr) | ||
| RU2017105353A (ru) | Соединения | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| JP2015505564A5 (hr) | ||
| JP2013542261A5 (hr) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| MX2020005518A (es) | Mezclas no racemicas y usos de las mismas. | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| PH12020551494A1 (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| JP2014504636A5 (hr) | ||
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 |